Stryker (SYK)
(Delayed Data from NYSE)
$335.61 USD
-1.54 (-0.46%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $335.50 -0.11 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Stryker (SYK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$363.14 | $406.00 | $297.00 | 7.71% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Stryker comes to $363.14. The forecasts range from a low of $297.00 to a high of $406.00. The average price target represents an increase of 7.71% from the last closing price of $337.15.
Analyst Price Targets (21)
Broker Rating
Stryker currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, 17 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 70.83% and 4.17% of all recommendations. A month ago, Strong Buy made up 69.57%, while Buy represented 4.35%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 17 | 16 | 16 | 16 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Evercore Partners | Vijay Kumar | Not Available | Strong Buy |
3/15/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
2/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/31/2024 | Canaccord Genuity | Caitlin Cronin | Not Available | Strong Buy |
1/30/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
11/9/2023 | Roth Capital Partners | Jason Wittes | Strong Buy | Strong Buy |
11/6/2023 | Truist Securities | Richard Newitter | Hold | Hold |
11/3/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 24 |
Average Target Price | $363.14 |
LT Growth Rate | 10.50% |
Industry | Medical - Products |
Industry Rank by ABR | 142 of 252 |
Current Quarter EPS Est: | 2.35 |